• Western blot analysis of extracts of various cell lines, using KLK13 antibody (STJ116486) at 1:3000 dilution. Secondary antibody: HRP Goat Anti-rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Enhanced Kit. Exposure time: 90s.

Anti-KLK13 antibody (1-277) (STJ116486)

SKU:
STJ116486

Shipping:
Free Shipping
Current Stock:
Host: Rabbit
Applications: WB/ELISA
Reactivity: Human/Mouse/Rat
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: PBS with 0.02% Sodium Azide, 50% Glycerol, pH 7.3.
Purification: Affinity purification
Concentration: Lot specific
Dilution Range: WB:1:500-1:2000
ELISA:Recommended starting concentration is 1 Mu g/mL. Please optimize the concentration based on your specific assay requirements.
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: KLK13
Gene ID: 26085
Uniprot ID: KLK13_HUMAN
Immunogen Region: 1-277
Specificity: Recombinant fusion protein containing a sequence corresponding to amino acids 1-277 of human KLK13 (NP_056411.1).
Immunogen Sequence: MWPLALVIASLTLALSGGVS QESSKVLNTNGTSGFLPGGY TCFPHSQPWQAALLVQGRLL CGGVLVHPKWVLTAAHCLKE GLKVYLGKHALGRVEAGEQV REVVHSIPHPEYRRSPTHLN HDHDIMLLELQSPVQLTGYI QTLPLSHNNRLTPGTTCRVS GWGTTTSPQVNYPKTLQCAN IQLRSDEECRQVYPGKITDN MLCAGTKEGGKDSCEGDSGG PLVCNRTLYGIVSWGDFPC
Tissue Specificity Expressed in prostate, breast, testis and salivary gland.
Protein Name Kallikrein-13
Kallikrein-Like Protein 4
Klk-L4
Database Links Reactome: R-HSA-381426
Reactome: R-HSA-6809371
Cellular Localisation Secreted
Alternative Antibody Names Anti-Kallikrein-13 antibody
Anti-Kallikrein-Like Protein 4 antibody
Anti-Klk-L4 antibody
Anti-KLK13 antibody
Anti-KLKL4 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance